Market revenue in 2023 | USD 10.8 million |
Market revenue in 2030 | USD 17.0 million |
Growth rate | 6.6% (CAGR from 2023 to 2030) |
Largest segment | Phase 4 |
Fastest growing segment | Phase 1 |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre Clinical, Phase 1, Phase 2, Phase 3, Phase 4 |
Key market players worldwide | Accenture PLC Class A, IQVIA Holdings Inc, Cognizant Technology Solutions Corp Class A, Linical Americas, International Business Machines Corp, Labcorp Holdings Inc, ArisGlobal, Capgemini SE, ITClinical, Icon PLC, TAKE Solutions, PAREXEL, Wipro Ltd ADR, United Biosource Corporation, FMD K&L, BioClinica |
Phase 4 was the largest segment with a revenue share of 75.93% in 2023. Horizon Databook has segmented the UAE pharmacovigilance market based on pre clinical, phase 1, phase 2, phase 3, phase 4 covering the revenue growth of each sub-segment from 2018 to 2030.
The increasing number of ADR reports, coupled with rising investment of government for the development of healthcare infrastructure in the country, is driving the market. Moreover, rising awareness regarding the adoption of PV services, along with the availability of PV platforms, which allow ease in reporting ADR, is anticipated to fuel the market growth.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account